Acrivon Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '25 Oct 10, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	58	188	111	253	-
Market Cap Growth	-73.80%	69.67%	-56.12%	-	-
Enterprise Value	-72.51	11.12	-12.88	129.01	27.88
Last Close Price	1.86	6.02	4.92	11.52	-
PE Ratio	-	-2.53	-1.80	-1.52	0
PB Ratio	0.43	1.06	0.91	1.48	0
P/TBV Ratio	0.50	1.15	0.90	0.28	-
P/FCF Ratio	-	-2.75	-2.52	-7.82	0
P/OCF Ratio	-	-2.86	-2.60	-8.38	0
EV/EBITDA Ratio	-	-0.13	0.19	-3.99	-1.73
EV/EBIT Ratio	-	-0.12	0.19	-3.95	-1.72
EV/FCF Ratio	-	-0.16	0.29	-4.00	-1.96
Debt / Equity Ratio	0.01	0.01	0.03	0.02	-0.21
Debt / EBITDA Ratio	-0.04	-0.04	-0.07	-0.15	-0.35
Debt / FCF Ratio	-0.04	-0.05	-0.11	-0.15	-0.40
Quick Ratio	10.23	10.43	9.58	19.61	34.18
Current Ratio	10.31	10.55	9.75	20.27	34.46
Return on Equity (ROE)	-53.54%	-54.07%	-41.41%	-44.53%	68.22%
Return on Assets (ROA)	-53.16%	-53.28%	-42.01%	-22.69%	-15.18%
Return on Capital (ROIC)	-505.72%	-700.53%	-226.29%	-115.19%	-236.50%
Return on Capital Employed (ROCE)	-58.18%	-58.62%	-44.78%	-23.46%	-15.61%
Earnings Yield	-139.42%	-39.53%	-55.69%	-65.63%	-
FCF Yield	-118.72%	-36.40%	-39.64%	-12.78%	-
Buyback Yield / Dilution	6.11%	-67.85%	0.47%	-41.38%	-
Total Shareholder Return	-	-67.85%	0.47%	-41.38%	-

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q